Alpha Tau Medical (NASDAQ:DRTS) Earns “Buy” Rating from HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 40.45% from the company’s current price.

DRTS has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. LADENBURG THALM/SH SH increased their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Piper Sandler increased their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, Citigroup boosted their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, March 11th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.50.

Alpha Tau Medical Stock Performance

NASDAQ:DRTS opened at $10.68 on Wednesday. Alpha Tau Medical has a 1 year low of $2.81 and a 1 year high of $10.85. The firm has a 50 day moving average of $7.79 and a 200-day moving average of $6.42. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $939.95 million, a P/E ratio of -15.94 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS) last posted its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). As a group, sell-side analysts anticipate that Alpha Tau Medical will post -0.5 EPS for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in DRTS. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical during the 4th quarter worth about $48,000. Envestnet Asset Management Inc. bought a new position in Alpha Tau Medical in the third quarter valued at approximately $62,000. Bank of America Corp DE boosted its stake in Alpha Tau Medical by 2,779.1% in the third quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after acquiring an additional 17,500 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new position in Alpha Tau Medical in the first quarter valued at approximately $132,000. 2.65% of the stock is owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.